Anaerobic infection therapy

被引:18
作者
Giamarellou, H [1 ]
机构
[1] Univ Athens, Sch Med, Dept Internal Med & Infect Dis, GR-11527 Athens, Greece
关键词
anaerobic infections; intraabdominal; resistance surveillance; newer antimicrobials; therapy;
D O I
10.1016/S0924-8579(00)00269-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Anaerobes are involved mainly in abdominal surgical infections and the Bacteroides fragilis group is still predominant in such infections. By definition surgery itself plays the major role in therapy while antibiotics have an adjunctive role. Depending on the source of the infection, several combinations of either an older cephalosporin for community acquired infections or a more advanced cephalosporin, an aminoglycoside, aztreonam or a quinolone with metronidazole or clindamycin for nosocomial infections, are acceptable therapeutic regimens. Cefoxitin, cefotetan, carbapenems and the: inhibitors may also be used as monotherapy. However whenever selecting an antibiotic to combat anaerobes the following points should be seriously considered. The Value of anaerobic cultures which should always be obtained in order to be used for local resistance surveillance. There is a lack of important newer antimicrobials active against anaerobes. Studies of newer antibiotics generally exclude critically ill patients and are chiefly made up of appendicitis cases which by definition end up with > 90% cure rate. The importance of hyperbaric oxygen in selected cases should be considered. (C) 2000 Published by Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:341 / 346
页数:6
相关论文
共 34 条
[1]  
[Anonymous], 1989, Anaerobic Infections in Humans
[2]   THE BACTERIOLOGY OF GANGRENOUS AND PERFORATED APPENDICITIS - REVISITED [J].
BENNION, RS ;
BARON, EJ ;
THOMPSON, JE ;
DOWNES, J ;
SUMMANEN, P ;
TALAN, DA ;
FINEGOLD, SM .
ANNALS OF SURGERY, 1990, 211 (02) :165-171
[3]  
BOHNEN JMA, 1992, ARCH SURG-CHICAGO, V127, P83
[4]  
BOHNEN JMA, 1994, ARCH SURG-CHICAGO, V129, P33
[5]  
BOURGAULT AM, 1997, CLIN INFECT DIS, V25, P237
[6]   PIPERACILLIN-TAZOBACTAM VERSUS IMIPENEM-CILASTATIN FOR TREATMENT OF INTRAABDOMINAL INFECTIONS [J].
BRISMAR, B ;
MALMBORG, AS ;
TUNEVALL, G ;
WRETLIND, B ;
BERGMAN, L ;
MENTZING, LO ;
NYSTROM, PO ;
KIHLSTROM, E ;
BACKSTRAND, B ;
SKAU, T ;
KASHOLMTENGVE, B ;
SJOBERG, L ;
OLSSONLILJEQUIST, B ;
TALLY, FP ;
GATENBECK, L ;
EKLUND, AE ;
NORD, CE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2766-2773
[7]  
CONDON R, 1995, INF DIS CLIN PRAC S3, V4, P150
[8]  
CONDON RE, 1996, INF DIS CLIN PRAC S1, V5, P2
[9]  
DELLINGER EP, 1995, INF DIS CLIN PRAC S3, V4, P163
[10]  
DUERDEN BI, 1994, CLIN INFECT DIS, V18, P253